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Introduction: Reverse transcriptase polymerase chain reaction 
(RT-PCR) assay has been proved to have high sensitivity and speci-
ﬁcity to detect anaplastic lymphoma kinase (ALK) rearrangements. 
The aim of this study was to investigate the response to crizotinib in 
patients of advanced non–small-cell lung cancer (NSCLC) with ALK 
rearrangements detected by RT-PCR.
Methods: Only patients with advanced NSCLC who had their ALK 
rearrangement status detected by RT-PCR were included in this anal-
ysis. The utility of RT-PCR and fluorescence in situ hybridization 
(FISH) assay were compared in patients who were treated with crizo-
tinib based on their positive ALK rearrangements.
Results: One thousand ten patients were included in this study. 
Among them, 104 patients were ALK RT-PCR positive and 53 of 
them received crizotinib treatment. Among 255 tumors simultane-
ously analyzed by FISH and RT-PCR, the latter successfully detected 
all the 25 tumors with arrangements, including two cases that were 
missed by FISH. The overall response rate and median progres-
sion-free survival of the 53 patients with ALK rearrangements who 
received crizotinib treatment were 60.4% (95% conﬁdence interval 
[CI], 47.2–73.6) and 8.4 months (95% CI, 6.75–10.05), respectively, 
which were similar to the 21 patients detected by FISH with overall 
response rate of 57.1% (95% CI, 33.3–76.2; p = 0.799) and median 
progression-free survival of 7.4 months (95% CI, 4.43–10.38; p = 
0.833) after crizotinib treatment. Interestingly, there were two patients 
responded to crizotinib had their ALK rearrangement detected by 
RT-PCR but not FISH.
Conclusions: RT-PCR should be considered as an alternative/supple-
mental approach to detect ALK fusion oncogene in NSCLC patients 
who might beneﬁt from crizotinib treatment.
Key Words: Non–small-cell lung cancer, anaplastic lymphoma 
kinase, Reverse transcriptase polymerase chain reaction assay, fluo-
rescence in situ hybridization, crizotinib.
(J Thorac Oncol. 2015;10: 1546–1552)
The dramatic responses to small molecule inhibitors observed in advanced NSCLC patients harboring relevant 
oncogenic mutations have greatly impacted personalized ther-
apies based on molecular features of each cancer patient. As 
an example, testing for somatic genetic alterations of epider-
mal growth factor receptor (EGFR) and anaplastic lymphoma 
kinase (ALK) has become a diagnostic routine for pulmonary 
adenocarcinoma.1–4 Therefore, the precise determination of 
their mutational status is the key to provide optimal cares in 
clinical practice.
Currently, EML4–ALK translocation detected by 
fluorescence in situ hybridization (FISH) is required before 
the initiation of crizotinib treatment. However, immuno-
histochemistry (IHC) has recently emerged as an alterna-
tive method for the detection of ALK rearrangements and 
has increasingly gained wide acceptance as a selection test 
for ALK inhibitors.5 The College of American Pathologists 
(CAP)/International Association for the Study of Lung Cancer 
(IASLC)/Association for Molecular Pathology (AMP) guide-
line also recommended ALK IHC might be considered as a 
screening method to select specimens for further FISH testing 
if carefully validated.6 Besides, RT-PCR is another alternative 
method that is rapid and convenient to perform. Unlike IHC 
and FISH, it is free from subjective bias in analysis and can 
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be readily applied to cytological specimens such as bronchial 
washing fluid or pleural effusion that may not be suitable to be 
prepared as formalin-ﬁxed and parafﬁn-embedded samples.7 
Several studies have showed its high sensitivity and speciﬁcity 
when compared with FISH.7–12 Moreover, Shan et al.13 reported 
eight ALK-expressing cases were all ALK negative by FISH 
but ﬁve of which had ALK fusion detected by RT-PCR. 
Teixidó et al.14 also found the incidence of EML4–ALK fusion 
was higher when detected by RT-PCR than the results of IHC 
or FISH analysis in their 200 patients with NSCLC. These 
observations suggested that RT-PCR could potentially iden-
tify extra patients who might beneﬁt from ALK inhibitors. In 
this regard, the Chinese Food and Drug Administration has 
approved ADx EML4–ALK fusion gene diagnostic kit to be 
used for RT-PCR to detect ALK rearrangements, and this par-
ticular assay has also been accepted by Chinese Anticancer 
Association. However, up to now, it is still largely unknown 
about the response to crizotinib for NSCLC patients having 
ALK rearrangement detected by RT-PCR.
To better clarify the clinical implication of RT-PCR 
to detect EML4–ALK fusion transcripts, we performed this 
study to investigate the response to crizotinib among Chinese 
advanced NSCLC patients who had positive ALK fusion 
detected by RT-PCR, and to compare its clinical value with 
the conventional FISH method.
PATIENTS AND METHODS
Patients and Procedures
Eligible patients were those NSCLC patients who had 
stage IV disease (International Association for the Study of 
Lung Cancer staging system version 7) and had their ALK 
fusion transcripts detected by RT-PCR at Shanghai Pulmonary 
Hospital, Tongji University School of Medicine, Shanghai, 
China. Among them, some cases were simultaneously analyzed 
by FISH and some cases were EGFR wild type. All the sam-
ples were conﬁrmed by pathologists. For the cytological sam-
ples, once the operator obtained biopsy tissue, it was divided 
into two parts: one part was sent to pathology, whereas another 
part was immediately placed in an RNase-free Eppendorf tube 
containing 500 μl of RNAlater (Cat No.AM 7021, life tech-
nologies) and stored at −20°C. Once the pathologist conﬁrmed 
more than 100 cancer cells, the RNAlater preserved part would 
be taken out to extract mRNA. For formalin-ﬁxed and parafﬁn-
embedded samples, a pathological evaluation was required to 
conﬁrm the tumor cell content exceeded 30% of the samples. 
Their clinical data included the age, gender, smoking status, 
Eastern Cooperative Oncology Group (ECOG) performance 
status (PS), brain metastasis status, and previous therapies. 
Nonsmokers were deﬁned as patients who had smoked less 
than 100 cigarettes in their lifetime, and ex-smokers were 
patients who had quit smoking at least 1 year before.
Tumor response was evaluated 1 month after the ﬁrst 
dose of crizotinib (250 mg, twice daily) and then every 2 
months afterward according to response evaluation criteria 
in solid tumors (version 1.1). Progression-free survival (PFS) 
was deﬁned as the time interval from the ﬁrst day of treatment 
to documented disease progression or death of any cause. All 
adverse events were assessed and classiﬁed by grade according 
to the national cancer institute common terminology criteria 
for adverse events (version 4.0). This study was approved by 
the ethics committee of Shanghai Pulmonary Hospital, Tongji 
University, Shanghai, China, and a written informed consent 
was obtained from each participant before the initiation of any 
study-related procedure.
RNA Preparation
The RNA was extracted from lung tumors as per stan-
dard protocols (RNeasy Mini Kit, Qiagen, Hilden, Germany 
or AmoyDx RNAKit, Amoy Diagnostics Co, Xiamen, China). 
This extraction method was optimized by the manufacturer to 
reverse formaldehyde modiﬁcation without further RNA degra-
dation and has proved to be an efﬁcient method to obtain RNA 
of sufﬁcient quantity for PCR ampliﬁcation in our laboratory.
ALK Rearrangement Detection
RT-PCR and FISH were used to detect the ALK rear-
rangement. The EML4–ALK fusion mRNA was detected 
using AmoyDx EML4–ALK Fusion Gene Diagnostic Kit (Cat 
No. ADx-FF04, Amoy Diagnostics Co, Xiamen, China), which 
is designed to detect 21 types of known ALK rearrangements 
including E6;A19, E6;A20, E6ins33;A20, E6;ins18A20, 
E13;A20, E13;ins69A20, E20;A20, E20;ins18A20, 
E14ins11;del49A20, E14;del14A20, E14;del38A20, 
E15del60;del71A20, E2;A20, E2;ins117A20, E3;ins53A20, 
E17;ins30A20, E17ins61;ins34A20, E17ins65;A20, 
E17;ins68A20, E17del58;ins39A20, and E18;A20. In brief, 
the mRNA extracted from the previous step was reverse-
transcribed to cDNA at 42°C, followed by PCR ampliﬁcation. 
The PCR condition of the cDNA was an initial denaturation 
at 95°C for 5 minutes, followed by 95°C for 25 seconds, 64°C 
for 20 seconds, and 72°C for 20 seconds to ensure the speci-
ﬁcity; and up to 31 cycles of 93°C for 25 seconds, 60°C for 
35 seconds, 72°C for 20 seconds. The details can be referred 
to our previous studies.15–20 To reduce the false-positive, we 
sequenced the 21 known variants to conﬁrm ALK fusion for 
the ﬁrst 20 patients and then every three patients with ALK 
RT-PCR-positive fusion, as described previously.18
The detection of EML4–ALK fusion by FISH analysis 
was performed by using a break-apart probe speciﬁc to the 
ALK locus on 4-μm thick tumor sections according to the 
manufacturer’s instructions (Vysis LSI ALK Dual Color, 
Break Apart Rearrangement Probe, Abbott Molecular, Abbott 
Park, IL). The tumor cells with their nuclei had one or more 
FISH signals of each color were enumerated. The ALK fusion 
was considered positive if on average 15% of the tumor cells 
showed a split red and green signal and/or an isolated (single) 
red signal. Otherwise, the specimen was classiﬁed as ALK 
FISH negative. The results obtained by FISH were analyzed 
using an Olympus fluorescence microscope.
Statistical Analysis
Statistical analysis was carried out with SPSS version 
19.0. Chi-square test or Fisher’s exact test was used to analyze 
correlations between ALK status and the clinical pathologic 
variables. The response rate among subgroups and survival 
was described with Kaplan–Meier methodology, and the 
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log-rank test was used to compare survival among subgroups. 
Results were considered signiﬁcantly different if the p value 
was less than 0.05 in a two-way analysis.
RESULTS
Patients’ Characteristics
From January 11, 2011 to August 30, 2014, 1010 patients 
whose tumor specimen was sufﬁcient for at least the RT-PCR 
were included in this study. Among them, 104 (10.3%) were 
identiﬁed as ALK positive and 53 of them received oral crizo-
tinib (Fig. 1). The baseline clinical characteristics are shown 
in Table 1. The patients harboring ALK rearrangements were 
found to be younger (median age 53 vs. 65 years, p = 0.001), 
more usually never smokers (p = 0.015), with adenocarcinoma 
histology (p = 0.002) and with wild-type EGFR (p < 0.001). 
There was no statistical difference observed based on the 
gender, ECOG PS, brain metastasis, previous treatment, and 
specimens type (Table 1).
A Comparison Between RT-
PCR and FISH Approaches
Among the 1010 specimens tested with RT-PCR assay, 
255 cases of them were simultaneously analyzed by FISH, 
which identiﬁed 9.8% (25 of 255) patients had positive EML4–
ALK fusion by using the cut-off value of 15% tumor cells har-
boring ALK-positive signal. Using this criteria, there were 
7.1% (18 of 255) cases considered as FISH negative although 
they had 5% to 14% ALK-positive cells. Interestingly, RT-PCR 
method detected two ALK-positive cases, who were consid-
ered negative by FISH. One case showed negative ALK by 
FISH test with 68% of cells had single copies of the 5′ ALK 
signal and numerous cells with doublets of the 5′ ALK signal 
combined with one 3′ ALK signal,16 and the other case showed 
10% of cells had ALK translocation. When using FISH as the 
standard procedure, the sensitivity and speciﬁcity of RT-PCR 
to detect ALK fusion were 100% and 99.1%, and the concor-
dance rate to FISH was 99.2% (Table 2).
The Response to Crizotinib
The response was evaluated in the 53 patients with 
advanced NSCLC and ALK RT-PCR positive. Among them, 
one patient had a complete response, 31 had a partial response 
and 13 got a stable disease. Thus, the objective response rate 
(ORR) was 60.4% (95% conﬁdence interval [CI], 47.2–73.6), 
and the disease control rate (DCR) was 84.9% (95% CI, 
75.5–94.3). Figure 2 shows the best change in percentile of 
the target lesions from baseline for patients with measurable 
disease (n = 50; best change is deﬁned as the best response 
across all time points), excluding three patients without mea-
surable lesions (pleural effusion). In total, 43 patients (86%) 
experienced tumor shrinkage. The two patients who had posi-
tive ALK fusion by RT-PCR but not by FISH achieved best 
tumor shrinkage of 75.0% and 52.4% after the treatment with 
crizotinib (Fig. 2, labeled with asterisks).
The ORR did not show statistical difference based 
on age (<65 vs. ≥65 years), gender, smoking status, ECOG 
PS, brain metastases status, lines of previous treatment, and 
specimen type (Fig. 3). The median time to ﬁrst documented 
objective response of the 32 responders (complete response or 
partial response) was 4.3 weeks (range, 3.1–11.1), and median 
response duration was 35.0 weeks (95% CI, 28.5–41.5).
Among the 21 patients who had positive ALK fusion per 
FISH and received crizotinib treatment, 12 achieved objec-
tive response and 7 got stable disease. Thus, the ORR was 
57.1% (95% CI, 33.3–76.2), and DCR was 90.5% (95% CI, 
95.2–76.2), which were similar to the ORR (p = 0.799) and 
DCR (p = 0.715) of the patients having positive ALK fusion 
by RT-PCR.
Survival Analysis
Survival analyses were performed in all 53 patients who 
received crizotinib therapy with a median follow-up duration 
of 20.3 months (95% CI, 16.80–32.23 mo). Among them, 15 
patients (28.3%) were still on ALK tyrosine-kinase inhibi-
tors, and 35 (66%) were alive at the last follow-up data of 
December 30, 2014. The median PFS (mPFS) was 8.4 months 
(95% CI, 6.75–10.05), whereas the median overall survival 
(OS) has not reached so far. Patients with ECOG PS 0–1 had 
a signiﬁcantly longer mPFS than those with ECOG PS 2–3 
(9.1 vs. 3.2 mo, p = 0.009).There was one patient with large-
cell carcinoma experienced disease progression a month later, 
whereas the other 52 patients with adenocarcinoma had mPFS 
of 8.6 months (95% CI, 7.67–9.53). However, the PFS did not 
show statistical difference based on age (<65 vs. ≥65 yr, 8.6 
vs. 7.4 mo, p = 0.948), gender (male vs. female, 8.4 vs. 9.1 
mo, p = 0.752), brain metastases status (without vs. with, 9.1 
vs. 5.2 mo, p = 0.355), and smoking status (never vs. ever, 8.6 
vs. 8.4 mo, p = 0.899). Additionally, we also performed the 
survival analysis in the 21 patients with FISH proven ALK 
fusion and found the mPFS was 7.4 months (95% CI, 4.43–
10.38), which was similar to the 8.4 months in patients with 
positive ALK fusion by RT-PCR (p = 0.833, Fig. 4).
Adverse Events
Thirty-ﬁve of 53 (66%) treated patients experienced 
adverse events, and most of them (32 of 35, 91%) were grade FIGURE 1. Flow chart of the study design.
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1 or 2 adverse events including visual disturbance (e.g., dip-
lopia, photopsia, blurred vision, and visual impairment), 
transaminitis, nausea, vomiting, diarrhea, fatigue, and con-
stipation. Three (6%) patients experienced grades 3–4 events 
including one case with grade 4 transaminitis, one with grade 
3 vomiting, and one with grade 3 esophagitis. Dose reduction 
occurred in two of them, and no other unexpected side effects 
were observed.
DISCUSSION
In this article, we reported for the ﬁrst time the response 
and safety of crizotinib for Chinese advanced NSCLC patients 
with positive EML4–ALK fusion detected by RT-PCR. In the 
enrolled 53 patients, we observed an ORR of 60.4% (95% CI, 
47.2–73.6), DCR of 84.9% (95% CI, 75.5–94.3), and mPFS 
of 8.4 months (95% CI, 6.05–10.75), which were similar to 
the ORR of 57.1% (95% CI, 33.3–76.2; p = 0.799), DCR 
of 90.5% (95% CI, 95.2–76.2; p = 0.715), and mPFS of 7.4 
months (95% CI, 4.43–10.38; p = 0.833) in the 21 patients 
whose ALK translocation was conﬁrmed by FISH. Although 
our study included ﬁrst-line, second-line, and later-line 
therapy of crizotinib, the mPFS in this study still fell within 
the range of 7.7 to 10.9 months as shown in the relevant phase 
I to III clinical trials.4,21–23 Interestingly, we also observed 
response to crizotinib in two patients, who had positive ALK 
fusion by RT-PCR but not by FISH (Table 2). 
EML4–ALK translocation was reported as a relatively 
low frequent rearrangement ranging from 1.5% to 6.7% among 
unselected Caucasian NSCLC patients.7,8,24–26 The frequency 
seems to be higher in Asian population and was reported as 
high as 5.1% to 10%27–33—part of the explanation was that in 
those studies, patients were selected from EGFR wild popu-
lation. Our previous study has shown the frequency of ALK 
rearrangement could be as high as 32.3% among selected 
patients who have never smoked and had adenocarcinoma har-
boring wild-type EGFR.15 In line with these results, we found 
the incidence of ALK rearrangement was 10.3% among all 
NSCLC patients in this study and was 26.8% in patients with 
wild-type EGFR. The subgroup analysis showed that ALK 
rearrangement was more likely to occur in patients who were 
younger, never smokers, and with adenocarcinoma histology, 
all of which were consistent with previous studies.34–36
TABLE 1. The Clinical Characteristics of Patients
Clinical Characteristics
Patients (n = 1010)
Crizotinib 
Treated  
(n = 53)
ALK Negative 
(n = 906)
ALK Positive 
(n = 104) P Valuea
Age (yr), median (range) 65 (22–80) 53 (22–78) 0.001 50 (22–76)
Gender
  Male 540 (59%) 59 (57%) 0.599 32 (60%)
  Female 366 (41%) 45 (43%) 21 (40%)
Smoking status
  Nonsmoker 602 (66%) 75 (72%) 0.015 42 (79%)
  Ex-smoker 136 (15%) 5 (5%) 2 (4%)
  Smoker 168 (19%) 24 (23%) 9 (17%)
Histology
  Adenocarcinoma 824 (92%) 103 (99%) 0.002 52 (98%)
  Nonadenocarcinoma 82 (9%) 1 (<1%) 1 (2%)
ECOG PS score
  0–1 710 (78%) 82 (79%) 0.910 42 (79%)
  ≥2 196 (22%) 22 (21%) 11 (21%)
Brain metastases
  No 657 (73%) 80 (77%) 0.414 43 (81%)
  Yes 249 (27%) 24 (23%) 10 (19%)
No. of previous chemotherapy
  0–1 377 (42%) 47 (45%) 0.529 29 (55%)
  2–4 529 (58%) 57 (55%) 24 (45%)
Specimen type
  Tissue specimens 151 (17%) 20 (19%) 0.490 14 (26%)
  Cytology specimens 755 (83%) 84 (81%) 39 (74%)
EGFR status
  Wild type 169 (19%) 62 (60%) 0.000 51 (96%)
  Unknown 737 (81%) 42 (40%) 2 (4%)
aThe p value was used to compare the clinical characteristics between ALK fusion positive and negative patients.
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase
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In this study, we also compared the results of RT-PCR 
with FISH in 255 patients who had sufﬁcient samples to be 
tested with both methods and observed a concordance rate of 
99.2%, which was consistent with the previous reports.7–13 In 
addition, by using RT-PCR approach, we found two patients 
responded to crizotinib who would otherwise be missed by 
conventional FISH, suggesting the clinical implication of 
using RT-PCR to detect EML4–ALK fusion mRNA. Similar 
to our results, Shan et al.13 also reported that among eight 
ALK-expressing cases by IHC, none of them were positive by 
FISH, but ﬁve were positive by RT-PCR.7 Similarly, Teixidó 
et al.14 reported that among 200 NSCLC patients in their 
study, RT-PCR detected more cases with EML4–ALK fusion 
gene (12.5%) than IHC (6.7%) and FISH analysis (4.5%). In 
this regard, the Chinese Food and Drug Administration has 
approved ADx EML4–ALK Fusion Gene Diagnostic Kit 
to be used for RT-PCR to detect ALK rearrangements, and 
this assay has also been accepted by Chinese Anti-cancer 
Association.37–40 However, other than this study, there is still 
no investigation with large population to validate the response 
to ALK inhibitor such as crizotinib in patients with positive 
ALK fusion oncogene detected by RT-PCR, despite of several 
encouraging case reports including ours.17,41,42
As the ﬁrst large-scale study, our investigation does 
have its limitations. First, this was a retrospective study 
with selected groups of patients, which could have inevita-
bly induced a selection bias. For example, there was more 
enrollment for patients with adenocarcinoma (some already 
FIGURE 2. Waterfall plot of best percent change from baseline of target lesions for 50 patients. *Response to crizotinib who 
had positive anaplastic lymphoma kinase (ALK) fusion by reverse transcriptase polymerase chain reaction (RT-PCR) but not by 
fluorescence in situ hybridization (FISH).
FIGURE 3. Response rate according to patient characteristics.
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had known wild-type EGFR), better ECOG PS, and who have 
never smoked. Second, the RT-PCR approach only targets 21 
known types of EML4–ALK fusion transcripts at this moment, 
which could have missed some other rare types of rearrange-
ment. Third, although we had large population of patients to 
start with (1010 patients), the actual population that received 
crizotinib was in fact small. A larger patient cohort using pro-
spective study is, therefore, needed to validate our ﬁndings. 
In addition, although RT-PCR is less expensive than FISH in 
detecting ALK in China because it has already been incorpo-
rated into a panel of mutation analysis including EGFR/ALK/
ROS1/RET/KRAS/BRAF/HER2 for lung adenocarcinoma, 
the actual cost effectiveness of RT-PCR comparing with that 
of FISH still need to be explored in future studies.
In conclusion, we found advanced NSCLC patients 
with ALK fusion transcripts detected by RT-PCR had similar 
response to crizotinib comparing with those detected by FISH. 
In addition to the high sensitivity and speciﬁcity comparable 
with FISH, RT-PCR also identiﬁed patients who responded to 
crizotinib who would otherwise be missed because of nega-
tive FISH. These observations suggested that RT-PCR may 
serve as an alternative/supplemental approach to ﬁnd NSCLC 
patients with EML4–ALK translocation who will be poten-
tially beneﬁt from ALK inhibitors such as crizotinib.
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